Core MAT Pharmacy Service



Kulvinder Singh Dosanjh
Medicines Management Pharmacist
CGL

Agenda

- 1.Why change?
- 2. Core MAT Service Aims and Components
- 3. Wellbeing Support
- 4. Missed and Late Dose Notifications
- 5. Supervision and monthly claims
- **6.Annual Pharmacist Review**
- 7. Activity Fees
- 8. Training and Assurance
- 9. Questions and Feedback

Why change?

- The standard supervised consumption model has not changed for years
- Equity for all (approx. 70% of service users are not on a supervised dose)
- Pharmacist support to SU was not measurable
- Previous Scheme could be considered as Transactional
- Improved quality and efficiency
- Enhanced service user safety and care
- Improved Pharmacy remuneration and engagement.

Core MAT Aims and Components

- A holistic approach to enhance the health and wellbeing of individuals affected by drugs
- Manage risks such as drug related deaths, overdose and other threats to health
- A quality driven service with a framework which underpins it




Evaluation-Initial Results

- Covering approximately 5000 service users (5% of all SU in structured treatment)
- Across 6 Pilot sites
- Utilising 540 pharmacies

- > Retention of all pharmacies
- ➤ 5% increase in pharmacies participating in Core MAT Service
- > An extra 3600 Service Users able to have a Pharmacist based intervention
- Average CGL Service monthly spend increased from £6532 to £10829

- Reduced time spent by pharmacy teams contacting services via phone/email with a single point of contact via PharmOutcomes
- > 50% reduction of MLDN processing times for admin teams
- Over 1000 Pharmacist reviews completed

Community Pharmacy Engagement Benefits



- Retention of all pharmacies that were engaged with the Supervised Consumption Service.
- Increase of 25 pharmacies across the 6 pilot sites in comparison to the previous model.
- A net increase of 5%.
- Value of Community Pharmacy Liaison Leads for implementation and relationship building with individual pharmacies and LPC's.

Wellbeing Support

Provided by an appropriate trained member of staff at the request of a

Service user


- Harm Minimisation advice
- Health living advice
- Signposting
- Referral
- Safeguarding

Missed and Late Dose Notifications

Quality, efficiency and safety benefits


- We base our treatment plans on risk
- The MLDNs highlight adherence concerns
- They alert Services to proactively support Service Users
- Supports Prescriber reviews and strengthen individual Service User treatment plans
- Enhance Service User safety to reduce the risk of disengagement, illicit on top use and overdose
- Provided assurance with a standardised approach for CGL services
- OHID/Coroner Concerns

Missed and Late Dose Notifications



Medicine type —————	
Methadone	
OBuprenorphine	
OMorphine	
Other	
Туре —	
O Methadone liquid	
O Physeptone liquid	
O Methadone tablets	
O Methadone ampoules	
Medicine type	
OMethadone	
Buprenorphine	
O Morphine	
Other	
Туре	
O Buprenorphine SL	
O Subutex	
○ Espranor	
O Suboxone	

Quality and Efficiency Benefits



- Average 475-800% increase in MLDN reports across 4 services
- Average of 20% increase in MLDN reporting across 2 services that were previously paying for missed notifications
- Includes non-supervised service users for the first time
- Direct PharmOutcomes/CRiiS reporting


Supervised / Non-supervised

- · Supervised consumption remains core to the scheme
- Trained and competent member of the Dispensing Team
- Simplified single data entry per Service User on PharmaOutcomes per month
- No need for daily data entry
- Registration of all Service Users
- Monthly declaration for all Service Users (Supervised and nonsupervised)

Registration

Registration date	05-Feb-2024
Name	
Date of Birth	Enter as dd-mmm-yyyy (eg 23-Feb-1989)
Gender	○ Male ○ Female
Ethnicity	Select an option 🗸
Postcode	Search
Address	
NHS Number	
5	
Please record the name of the	e clients keyworker
Keyworker	

Personal Demographic Service



Patient Lookup via the Personal Demographic Service (PDS)	
More information abou	ut PDS (opens in new tab).
	this service requires that the PDS service is used tient details at least once .
Search by patient details Please provide a minimum via PDS' to try and find the	of the patient's Date of Birth and NHS Number. Press 'Lookup e patients details:
Date	of Birth Enter as dd-mmm-yyyy (eg 23-Feb-1989)
NHS	Number The patient's verified NHS Number
	Lookup via PDS

Monthly Supervised Non-Supervised Claims

CGL (Pre	_ Monthly Superviview)	vised / Unsupervised Dispensing
	e ensure only one monthly claim drug they are prescribed	is submitted per patient for
	Provision Date 05-Feb-20	024
	Client name You cannot i	register new Client name
	Medicine type	
	O Methadone	
	OBuprenorphine	
	O Morphine	
	Other Medicine type	
dis	Month of	<u> </u>
Sup	ervised consumption O Yes) No
c	Were all missed ○ Yes ○ doses/late collections reported?) No
	you dispensed at least ten days ce User this month?	worth of medication for this
	10 or more days Yes) No

┌ Medicine type ─────
Methadone
OBuprenorphine
○ Morphine
Other
Type
O Methadone liquid
O Physeptone liquid
O Methadone tablets
O Methadone ampoules
Medicine type
○ Methadone
Buprenorphine
O Morphine
Other
Туре
O Buprenorphine SL
○ Subutex
○ Espranor
○ Suboxone

How many supervisions were conducted this month? Number of supervisions this month Were all missed ○ Yes ○ No doses/late collections reported? Missed/late doses Please ensure all missed doses and late collections for this month have been reported here Have you dispensed at least ten days worth of medication for this Service User this month? **10 or more days** ○ Yes ○ No

Quality and Efficiency Benefits

Pharmacist Reviews

- 1081 (20%) Quarterly MAT Reviews completed by pharmacies in all pilot CGL sites.
- 16% of Service Users reported adherence to prescribed MAT as an issue.
- 12% of Service Users on sub-optimal dose and using illicit drugs.
- Naloxone supply/referral to CGL on 109 occasions.
- Healthy living advice including support with smoking cessation, diet and exercise advice, as well as support with mental and physical health with appropriate referral or signposting.

Quality, efficiency and safety benefits

- Adherence to MAT and issues raised
- 2. Adherence to other medication and issues raised
- 3. Highlight any possible contra-indications and drug interactions
- 4. Review safe storage of MAT and Naloxone availability
- 5. Provide healthy living interventions. Signposting and referral as appropriate.

Client name			
Client name	You cann	not register	new Client name
- Consent for service			
Does service user c	onsent 1	to an An	nual Pharmacist Review?
C	Consent:	Yes	Consent given
		○ No	Consent not given
passed to: CGL. For reporting results t	to CGL		e information you provide wil Consent to share given
If you give consent for passed to: CGL. For reporting results to	to CGL	Yes	
If you give consent for passed to: CGL. For reporting results to	to CGL share:	Yes	Consent to share given
If you give consent for passed to: CGL. For reporting results to Consent to Consent to Consent to Does the Service Use	to CGL share:	● Yes ○ No	Consent to share given Consent to share not given
If you give consent for passed to: CGL. For reporting results to Consent to Consent to Consent to Consent for service Does the Service Use help in the review)?	so CGL share:	Yes No note to SCI	Consent to share not given
If you give consent for passed to: CGL. For reporting results to Consent to Consent to Consent to Consent for service Does the Service Use help in the review)?	so CGL share:	Yes No note to SCI	Consent to share given Consent to share not given

Allergies and ADRs	
Are you allergic to a Yes	any medication?
○ No	
Please provide details	Please do not enter patient identifiable information
Have you suffered any Adverse Drug Reactions?	● Yes ○ No
If yes, please provide details	Please do not enter patient identifiable information

Current MAT Drug Prescribed	Methadone liquid ✓
Doses	
Is the service User Adherer	nt to their prescribed MAT?
Adherent to their pr	rescribed MAT?
○ Yes	
○ No	
Over the last 28 days how r	nany doses have not been
	ny pattern to missed doses? (i.e. missing
	y other day, missing regular days in the
,	s for this? E.g. side effects, using illicit
drugs on top, difficulty taki	ng
Please state reasons	
	Please do not enter patient identifiable information
Is there any support they w	ould like to improve their adherence?
Support required?	
Yes	
○ No	
What support would they like?	
	Please do not enter patient identifiable information


Is the Service User on an optimal MAT Dose? (For Methadone this is
60-120mg, buprenorphine 12-16mg)
On an optimal MAT Dose?
○Yes
● No
If no, is the Service User using illicit drugs on top?
Illicit drugs on top?
○Yes
● No
Is the Service User stable on a sub-optimal dose with no on top
illicit drug use, or on a reducing dose?
○ Yes ○ No
○ No
Is there any support they would like regarding their MAT
medication and dose
Yes
○ No
If yes, please give details
Please do not enter patient identifiable information

Other Current Medication and Adherence
What medications are Paracetamol 500mg caplets (Alliance He
you currently
prescribed? (including
отс)
Dose two tablets prn
Does the service user understand why they are taking this medication?
Reason for taking medication understood?
○Yes
No No
O 140
Service users understanding as to why they are taking this
medication and/or Pharmacist advice provided?
Understanding
/2
Please do not enter patient identifiable information
┌ Adherent
○ Yes
© No
● No
If not adherent, what are
the concerns/barriers? E.g.
Side-effects/difficulty taking
their medication etc Please do not enter patient identifiable information
2nd medicine to be ○ Yes ○ No
recorded?
recorded :

Contra-indications and Interactions			
Are th	Are there any contra-indications with current medications being		
taken?	taken?		
Г	Any contra-indications?		
	Yes		
	○ No		
	If yes, please give		
	details:		
		<i>I</i>	
		Please do not enter patient identifiable information	
	Are there any drug interactions with current medications being taken?		
Γ	┌ Any drug interactions?		
	Yes		
	○ No		
	If yes, please give		
	details:		
		2	
		Please do not enter patient identifiable information	

Naloxone —
Does the Service User have a Naloxone kit?
○ Yes
● No
If no, has the service user been trained and supplied by the
Pharmacy?
Trained and supplied?
○ Yes
● No
Has the service user been referred to alternative Pharmacy/CGL
Service?
OPharmacy
○ Service
Please Tick one

Safe	e Storage
	Does Service User have a Safe Storage box? Yes No
	Please refer to local CGL Service O Yes O No





Activity Fees

Activity	Fee
Core MAT Offer	£7.50 per month per Service User
Completed Annual MAT Review	£30
Supervised Consumption - Methadone	£2.00
Supervised Consumption - Espranor	£2.00
Supervised Consumption – Buprenorphine sublingual	£2.50

Training and Assurance

- CPPE Training and Declaration of Competence
- Dispensing Team competence
- Annual Training Event for Pharmacy Team
- Participation in Annual Audit
- PharmOutcomes Data Monitoring
- CGL Investment

Questions and Feedback

Service User

"Really nice team and the pharmacist is supportive a couple of days ago when I was emotional. Happy to continue with reviews as took little time."

"Everything good with review, wished to increase 10mg and happy this is now raised with recovery worker and prescriber."

Pharmacy

"Very good now that we are familiar with the templates it doesn't take as much time to submit end of month data."

"I feel the three monthly reviews are a good idea, they helped me as a new manager get to know our customers better, it helped build rapport."

Service

"Integration and uptake in missed pickups being reported is now going well and received well by staff. Wellbeing checks and feedback and quarterly reviews have been received well."

"Good that we can identify sporadic collections from the data and that every missed pickup is recorded in the flash compared to when it was just 3 days missed previously.

LPC

"The Pharmacies are now being recognised for the work they do with all substance misuse patients regardless of supervised."

"All the pharmacists I've spoken to have said how useful they think the quarterly reviews are, they say feedback from the clients has also been good."